Melissa Baird, the Chief Operating Officer of Hims & Hers Health, Inc. (NYSE:HIMS), recently executed a series of stock ...

Citigroup has recently reduced Hims & Hers Health Inc (HIMS) stock to Sell rating, as announced on January 10, 2025, according to Finviz. Earlier, on January 7, 2025, BTIG Research had initiated the ...

San Francisco—Boughton Soleil, the Chief Legal Officer of Hims & Hers Health, Inc. (NYSE:HIMS), recently executed a series of ...

Discover why Hims & Hers Health is a top telehealth leader with impressive growth potential and a promising future for ...

In recent trading, Hims & Hers Health Inc (HIMS) stock price has shown some volatility, fluctuating 9.60% over the last five trades and -10.88% over the past 30 trades. This represents a notable shift ...

Hims & Hers Health ( HIMS 6.30%) is coming off a fantastic year in 2024 when its share price skyrocketed 172%. The telehealth ...

Financial writer highlights undervalued Hims & Hers Health with impressive growth potential and innovative product launches, ...

In other news, Novo Nordisk announced the results from its phase 3b STEP UP semaglutide trial today. Specifically, the ...

Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and ...

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Atricure (ATRC – Research Report) and Hims ...

Hims & Hers (HIMS) is down -6.5%, or -$1.81 to $26.13.Stay Ahead of the Market:Discover outperforming stocks and invest smarter with Top ...

Below is Validea's guru fundamental report for HIMS & HERS HEALTH INC (HIMS). Of the 22 guru strategies we follow, HIMS rates highest using our P/B Growth Investor model based on the published ...